Second Affiliated Hospital of Guangzhou Medical University
广州医科大学附属第二医院
Listed for 14 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Second Affiliated Hospital of Guangzhou Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌4 papers led
- Hepatocellular carcinoma肝细胞癌39 papers led18 open trials led
- Stomach cancer胃癌4 papers led1 open trial led
- Osteosarcoma骨肉瘤1 paper led
- Neuroblastoma神经母细胞瘤1 paper led
- Multiple myeloma多发性骨髓瘤5 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
- Beta thalassaemiaβ 地中海贫血2 papers led
- Haemophilia A血友病 A0 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
- IgA nephropathyIgA 肾病0 papers led
- Hereditary angioedema遗传性血管性水肿0 papers led
Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 4 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
24 hospitals in Guangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingConcurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2022-12
- Registry
- NCT05717790
Age 18 years to 70 years (registered criteria)
Led by Fourth Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuangzhou, Guilin, Liuzhou, Wuzhou, Zhongshan
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Phase
- Phase 1
- Started
- 2021-11
- Registry
- NCT05194982
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Homeobox B2 promotes malignant behavior and contributes to the radioresistance of nasopharyngeal carcinoma by regulating forkhead box protein O1.
- Specific immunological characteristics and risk factor of XBB variants re-infection in nasopharyngeal carcinoma patients after BA.5 infection.
- Induction of ferroptosis in human nasopharyngeal cancer cells by cucurbitacin B: molecular mechanism and therapeutic potential.
- Metastatic Patterns and Prognosis of de novo Metastatic Nasopharyngeal Carcinoma in the United States.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 39 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.
15 hospitals in Guangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 19
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06904183
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingLenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06904196
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06397222
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingDEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06397235
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingCheckpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06482801
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingLenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06492395
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingNeoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06492408
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingY-90 SIRT for Unresectable HCC Larger Than 7cm
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06707233
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
- Phase
- Phase 3
- Started
- 2023-08
- Registry
- NCT05985798
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSIRT for Potentially Resectable HCC
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05994859
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingLenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05608213
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingTrametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2021-01
- Registry
- NCT04803318
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingIntratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2021-03
- Registry
- NCT04952272
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingIntra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
- Phase
- Phase 2
- Started
- 2020-11
- Registry
- NCT04770207
Age 18 years to 99 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingInfusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2019-01
- Registry
- NCT03949231
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2018-11
- Registry
- NCT03755739
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- Phase
- Phase 1
- Started
- 2017-07
- Registry
- NCT03198546
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou
- Not yet recruitingYttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07657273
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Enrolling by invitationObservational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06712017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led39
- Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC.
- Quinacrine Inhibits Hepatocellular Carcinoma Growth and Enhances the Anti-HCC Effects of Lenvatinib.
- Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial.
- Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinoma.
- Evaluation of the efficacy and safety of combined surgery with intraoperative radiotherapy and postoperative PVC for hepatocellular carcinoma with mPVTT.
- Deciphering the influence of AP1M2 in modulating hepatocellular carcinoma growth and Mobility through JNK/ErK signaling pathway control.
- Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma.
- The Imaging Value of 18F-FAPI PET/CT in Sorafenib-Induced Cardiac Dysfunction in Patients with Hepatocellular Carcinoma: Compared with 18F-FDG PET/CT.
- The value of acetylation reader YEATS2 in hepatocellular carcinoma management.
- Intratumoral Lactate Depletion Based on Injectable Nanoparticles-Hydrogel Composite System Synergizes with Immunotherapy against Postablative Hepatocellular Carcinoma Recurrence.
- Circ_MAPK9 promotes STAT3 and LDHA expression by silencing miR-642b-3p and affects the progression of hepatocellular carcinoma.
- Centrosome amplification-related signature correlated with immune microenvironment and treatment response predicts prognosis and improves diagnosis of hepatocellular carcinoma by integrating machine learning and single-cell analyses.
- Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy.
- Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort
- TREM1+ tumor-associated macrophages secrete CCL7 to promote hepatocellular carcinoma metastasis.
- Anti-CTLA-4 antibody self-presented dendritic cell nanovesicles boost the immunotherapy of hepatocellular carcinoma after microwave ablation.
- Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
- Liver transplantation following two conversions in a patient with huge hepatocellular carcinoma and portal vein invasion: A case report.
- Dynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma.
- Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma.
- Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study.
- Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases.
- Influence of AFP on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma.
- Identification and validation of a prognostic-related mutant gene DNAH5 for hepatocellular carcinoma.
- T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
- Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy.
- Study of the Intersegmental Veins Between S5 and S8 Based on 3D Reconstruction.
- High Expression of Ten Eleven Translocation 1 Is Associated with Poor Prognosis in Hepatocellular Carcinoma.
- Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.
- Downregulation of MCF2L Promoted the Ferroptosis of Hepatocellular Carcinoma Cells through PI3K/mTOR Pathway in a RhoA/Rac1 Dependent Manner.
- CEP192 is a novel prognostic marker and correlates with the immune microenvironment in hepatocellular carcinoma.
- Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
- Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation.
- Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src.
- Sublethal heat stress-induced O-GlcNAcylation coordinates the Warburg effect to promote hepatocellular carcinoma recurrence and metastasis after thermal ablation.
- One-step preparation of photoclick method for embolic microsphere synthesis and assessment for transcatheter arterial embolization.
- PRR34-AS1 sponges miR-498 to facilitate TOMM20 and ITGA6 mediated tumor progression in HCC.
- Dual inhibition of reactive oxygen species and spleen tyrosine kinase as a therapeutic strategy in liver fibrosis.
- IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status36
- Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
- Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
- Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
- Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
- DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
- Y-90 SIRT for Unresectable HCC Larger Than 7cm
- Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
- Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
- Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
- Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
- SIRT for Potentially Resectable HCC
- Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
- Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
- Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
- Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
- Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
- Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
- DEB-TACE+HAIC vs. HAIC for Large HCC
- Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
- SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC
- Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
- TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
- DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC
- Donafenib Plus Sintilimab for Advanced HCC
- TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
- TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
- TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
- Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
- TACE Combined With Iodine-125 Seeds Implantation for HCC
- Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
- HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
- Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Cancer
Stomach cancer
胃癌Led 4 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.04%.
- Open trials as a site
- 0
- led by another institution
15 hospitals in Guangzhou for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Registry
- NCT05187338
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Circular RNA profiling and functional analysis implicate circ-ANKRD36C as a potential prognostic biomarker in gastric cancer.
- Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer.
- Diagnostic value of MRI-DWI signal intensity value combined with serum PGI, PGII and CA199 in early gastric cancer.
- Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer.
All its trials on ClinicalTrials.gov, any status2
Cancer
Osteosarcoma
骨肉瘤Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
30 hospitals in Guangzhou for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)3
- miR-19 Promotes Cell Proliferation, Invasion, Migration, and EMT by Inhibiting SPRED2-mediated Autophagy in Osteosarcoma Cells.
- LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/FOXA1 axis.
- Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression.
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
22 hospitals in Guangzhou for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
14 hospitals in Guangzhou for multiple myeloma175 hospitals in China for multiple myeloma
No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led5
- Proteasomal inhibitors induce myeloma cell pyroptosis via the BAX/GSDME pathway.
- Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma.
- High expression of CPNE5 and CPNE9 predicts positive prognosis in multiple myeloma.
- Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis.
- Increased expression of IFI16 predicts adverse prognosis in multiple myeloma.
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Beta thalassaemia
β 地中海贫血Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
18 hospitals in Guangzhou for beta thalassaemia133 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Blood disorders
Haemophilia A
血友病 ALed no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Guangzhou for haemophilia A132 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
More papers found outside PubMed (not counted)1
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Guangzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
20 hospitals in Guangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Fasting alleviates bleomycin-induced lung inflammation and fibrosis via decreased Tregs and monocytes.
- DDR1 activation in macrophage promotes IPF by regulating NLRP3 inflammasome and macrophage reaction.
- TSSK4 upregulation in alveolar epithelial type-II cells facilitates pulmonary fibrosis through HSP90-AKT signaling restriction and AT-II apoptosis.
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Guangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
Hereditary angioedema
遗传性血管性水肿Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Guangzhou for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Getting in touch
Name card to show staff or a driver
广州医科大学附属第二医院
Second Affiliated Hospital of Guangzhou Medical University
广州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Second Affiliated Hospital of GuangZhou Medical University